Drug profile · INN
sacituzumab govitecan-hziy
TRODELVY
sacituzumab govitecan-hziy (TRODELVY) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — sacituzumab govitecan-hziy
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
sacituzumab govitecan-hziy (TRODELVY) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase I inhibitor
Primary target: DNA topoisomerase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.
Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape
Datroway and Trodelvy, two TROP2-targeting antibody-drug conjugates, are poised to enter a head-to-head competition in the first-line treatment of triple-negative breast cancer (TNBC). This evolving landscape presents significant strategic considerations for pharmaceutical business development and investment.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sacituzumab govitecan-hziy?
sacituzumab govitecan-hziy (TRODELVY) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for sacituzumab govitecan-hziy?
TRODELVY is a marketed brand name for sacituzumab govitecan-hziy. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sacituzumab govitecan-hziy?
sacituzumab govitecan-hziy has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.